Senti Biosciences Inc (SNTI)

Dec 16, 2024, 8:00 AM EST - 4 weeks ago

Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics

Dec 3, 2024, 8:00 PM EST - 6 weeks ago

Senti Biosciences Announces New Employment Inducement Grants

Dec 2, 2024, 11:44 AM EST - 6 weeks ago

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Dec 2, 2024, 7:10 AM EST - 6 weeks ago

Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing

Dec 2, 2024, 7:02 AM EST - 6 weeks ago

Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML

Nov 14, 2024, 4:05 PM EST - 2 months ago

Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights

Sep 3, 2024, 8:15 AM EDT - 4 months ago

Senti Bio to Participate in Upcoming Investor Conferences

Aug 13, 2024, 4:05 PM EDT - 5 months ago

Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Aug 5, 2024, 8:05 AM EDT - 5 months ago

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Jul 16, 2024, 8:30 AM EDT - 6 months ago

Senti Bio Announces Reverse Stock Split

Jul 1, 2024, 8:05 AM EDT - 7 months ago

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

May 13, 2024, 8:15 AM EDT - 8 months ago

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

May 9, 2024, 4:05 PM EDT - 9 months ago

Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights

Apr 30, 2024, 8:05 AM EDT - 9 months ago

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Mar 21, 2024, 4:05 PM EDT - 10 months ago

Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

Jan 5, 2024, 4:05 PM EST - 1 year ago

Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program

Dec 22, 2023, 6:30 AM EST - 1 year ago

Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Nov 13, 2023, 4:15 PM EST - 1 year ago

Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates

Nov 12, 2023, 1:45 AM EST - 1 year ago

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

AZN BNTX BSX

Nov 6, 2023, 4:05 PM EST - 1 year ago

Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China

Oct 31, 2023, 9:06 AM EDT - 1 year ago

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer Annual Meeting

Sep 27, 2023, 9:05 AM EDT - 1 year ago

Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting

Sep 26, 2023, 4:05 PM EDT - 1 year ago

Senti Bio to Participate in Upcoming Conferences

Aug 11, 2023, 8:35 AM EDT - 1 year ago

Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates

Aug 10, 2023, 8:35 AM EDT - 1 year ago

Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners

May 20, 2023, 8:05 AM EDT - 1 year ago

Senti Bio Highlights Initial Gene Circuit Data From Collaborations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 9, 2023, 4:05 PM EDT - 1 year ago

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

May 2, 2023, 4:45 PM EDT - 1 year ago

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

Apr 17, 2023, 8:45 AM EDT - 1 year ago

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

Mar 22, 2023, 5:09 PM EDT - 1 year ago

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

Mar 8, 2023, 5:30 PM EST - 2 years ago

Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

BBAI

Feb 21, 2023, 12:04 PM EST - 2 years ago

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Senti Bioscience, Inc. (SNTI) Investigation

Feb 1, 2023, 4:05 PM EST - 2 years ago

Senti Bio to Present at the SVB Securities Global Biopharma Conference

Jan 27, 2023, 8:00 AM EST - 2 years ago

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

Dec 19, 2022, 7:55 AM EST - 2 years ago

Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

Dec 11, 2022, 9:00 AM EST - 2 years ago

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

Nov 23, 2022, 7:55 AM EST - 2 years ago

Senti Bio to Host Investor Event Highlighting SENTI-202 at the 2022 ASH Annual Meeting

Nov 10, 2022, 7:55 AM EST - 2 years ago

Senti Bio Reports Third Quarter Financial Results and Pipeline Updates